TheraCea Pharma has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $275,000 to conduct research and development (R&D) work on developing new diagnostic tools for fast and conclusive assessment of therapy in cancer patients and potentially neurological disorders.

TheraCea team is leveraging foundational scientific research to develop a new class of diagnostic agents aimed at early detection of treatment efficacy in cancer patients. This innovative approach enables patients and healthcare providers to assess the success of cancer therapies within weeks, rather than the months typically required, potentially enhancing patient outcomes and improving treatment decision-making. Ultimately, this advancement stands to benefit society by reducing uncertainty for patients and facilitating more timely and better informed healthcare responses.